Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, 6 days ago

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
Stephen Padilla, 10 Nov 2020
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.

Pioglitazone reduces cardiovascular events in T2D patients with CVD history

06 Apr 2020

Use of pioglitazone is associated with a reduced risk of major adverse cardiovascular events (MACE) and is recommended in patients with or at high risk of type 2 diabetes (T2D), particularly those with a history of established cardiovascular disease (CVD), suggests a study.

In addition, there have been significant decreases observed in renal disease progression regardless of baseline renal function.

PubMed, Embase and the Cochrane Library were searched for randomized controlled trials (RCTs) comparing pioglitazone with any control. Cardiovascular outcomes were as follows: MACE (defined as the composite of nonfatal myocardial infarction, nonfatal stroke and cardiovascular death), hospitalization for heart failure and all-cause mortality. Renal outcomes included change in urinary albumin to creatinine ratio and 24-hour urinary protein excretion.

Twenty-six studies involving 19,645 participants met the eligibility criteria. Pioglitazone led to a decrease in MACE risk (risk ratio [RR], 0.8, 95 percent confidence interval [CI], 0.7–0.9) in patients with a history of established CVDs but not in those without (RR, 1.0, 95 percent CI, 0.7–1.3).

For individual components, pioglitazone reduced the risks of nonfatal myocardial infarction (RR, 0.8, 95 percent CI, 0.6–1.0) and nonfatal stroke (RR, 0.8, 95 percent CI, 0.7–0.9) in patients with a history of established CVDs. No treatment effect was seen on cardiovascular death (RR, 1.0, 95 percent CI, 0.7–1.2) regardless of the presence of established CVDs.

However, pioglitazone increased the risk of hospitalization for heart failure (RR, 1.3, 95 percent CI, 1.1–1.6) and showed no effect on all-cause mortality (RR, 1.0, 95 percent, 0.8–1.1). In addition, pioglitazone led to an 18.5-percent (weighted mean difference, 18.5 percent, 95 percent CI, 21.1–16.0) decrease in albuminuria, with benefits also seen in those with different renal function categories.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, 6 days ago

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
Stephen Padilla, 10 Nov 2020
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.